[{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Drug Innovation Ventures at Emory","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altesa BioSciences, Inc., Launches Operations to Develop, Commercialize Drugs for Respiratory Viruses and Global Viral Threats","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Altesa BioSciences Recognizes Co-Founder and Partner for Major NIH Research Grant to Discover New Antiviral Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altesa BioSciences to Initiate Clinical Trials of Promising Antiviral","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Altesa Biosciences
BTA798 (Vapendavir) has shown promising preclinical and clinical data demonstrating effective control of certain respiratory viruses, can potentially be used to treat epidemic hand, foot and mouth disease (HFMD) and HRV infection in COPD Patients.
With the newly announced AViDD award, Altesa options include relevant compounds advanced by DRIVE stemming from Emory’s Antiviral Countermeasure Development Center.
The collaboration includes a license to ALT-2023, a broadly active nucleoside analogue that is late stage preclinical development, as well as options to additional compounds addressing RNA viruses.